ClinicalTrials.gg
TerminatedNCT01458119AT1001-041Updated Oct 2, 2018Results posted

Open-Label Phase 3 Long-Term Safety Study of Migalastat

A Phase 3 interventional study of migalastat hydrochloride in Fabry Disease, sponsored by Amicus Therapeutics. Terminated at 25 sites in 13 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-10-02.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Why this study was terminated
Amicus Therapeutics discontinued Study AT1001-041 for logistical reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
3rd of 20
85 · median 20
Started
2011
with 4 others
Phase 3
11 of 20
2 open now
Registered
9th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 3rd largest by enrollment, is one of 5 that started in 2011, is one of 11 in phase 3, and was the 9th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

This was a long-term, open-label study of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) in participants with Fabry disease who completed treatment in a previous monotherapy trial with migalastat.

Read the detailed description

Study AT1001-041 was an open-label, noncomparative, multicenter, long-term extension study for participants with Fabry disease who completed treatment in one of three previous trials of migalastat (AT1001-011 [NCT00925301], AT1001-012 [NCT01218659], or FAB-CL-205 [NCT00526071]). In these trials, migalastat was given as monotherapy. This was an extension study designed to evaluate the long-term safety and efficacy of migalastat for the treatment of Fabry disease. Study visits occurred every 6 months (m). Visit evaluations included physical examinations, clinical laboratory parameters, adverse events, and participant reported outcomes.

The study consisted of a Baseline Visit, which was performed at the time of the final visit of the previous study, followed by clinic visits every 6 m for each year of the study. Study assessments included a physical examination, echocardiography, laboratory parameters, and participant-reported outcomes. Since participants enrolled in the study at varying time points based on the completion of the preceding migalastat study, treatment duration varied among participants. No maximum treatment duration was defined. There were no control groups in this study; all participants received migalastat as a 150-mg capsule taken orally once every other day (QOD) and inactive reminder capsules on alternate days.

The sponsor (Amicus Therapeutics) discontinued Study AT1001-041 for logistical reasons and not due to either safety concerns or lack of efficacy. For participants who were ongoing in Study AT1001-041 at the time of discontinuation, the investigators were offered participation in a similar open-label, long-term migalastat treatment study (AT1001-042 [NCT02194985]) for participants ongoing at discontinuation.

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Amicus Therapeutics
  • AT1001
  • Galafold
  • Migalastat
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed migalastat treatment in a previous Fabry disease protocol
  • Both male and female participants were enrolled
  • Age 16 years or older
  • Male and female participants had to agree to use protocol-identified acceptable

Exclusion criteria

Exclusion Criteria:

  • Estimated (eGFR) in the previous study was \<30 milliliters/minute/1.73 square meters (mL/min/1.73 m\^2) unless there was a measured GFR available within 3 m of the Baseline Visit that was >30 mL/min/1.73 m\^2
  • Had undergone, or was scheduled to undergo, kidney transplantation or was currently on dialysis
  • Pregnant or breast feeding
  • Treated with another drug (except migalastat) within 30 days of study start
  • Unable to comply with study requirements, or deemed otherwise unsuitable for study entry, in the opinion of the investigator
  • Had documented , stroke, unstable angina, or myocardial infarction within the 12 m before the Baseline Visit
  • Had , unstable cardiac disease in the opinion of the investigator
  • Had a history of allergy or sensitivity to migalastat (including ) or to other iminosugars
  • Required treatment with Glyset (miglitol) or Zavesca (miglustat)
  • Had any intercurrent illness or condition that may have precluded the participant from fulfilling the protocol requirements
  • Had a severe or unsuitable concomitant medical condition
  • Had a clinically significant abnormal laboratory value and a clinically significant finding at the Baseline Visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Migalastat

    Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.

    Drug: migalastat hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered migalastat that did not necessarily have a causal relationship with the treatment. Each AE was recorded at the time of reporting; visits typically occurred every 6 months. A TEAE was defined as an AE starting on or after the first study drug administration date. Serious AEs were life-threatening or resulted in death, persistent or significant incapacitation, inpatient or prolonged hospitalization, or a congenital anomaly. The criteria for AE severity were: Mild: minimal discomfort, does not interfere with normal everyday activities; Moderate: sufficiently discomforting, interferes with normal everyday activities; Severe: prevents normal everyday activities. The number of participants experiencing TEAEs is presented for those who received migalastat treatment. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline to End of Follow-up (30 days after the end of this 42-month study), with AE reporting occurring at each study visit, which occurred once every 6 months.

Secondary outcomes

  1. Annualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)

    The annualized rate of change of the eGFR was assessed per participant by the slope of the simple linear regression between the observed values and the assessment times. It was calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (eGFR \[CKD-EPI\]) and the Modification of Diet in Renal Disease (MDRD) equation (eGFR \[MDRD\]). The equations are as follows: eGFR \[MDRD\] = 175 \* (Serum Creatinine)\^-1.154 \* (Age)\^-0.203 \* 1.212 (if black or African American) \* 0.742 (if female); eGFR \[CKD-EPI\] = 141 \* min(serum creatinine/kappa,1)\^alpha \* max(serum creatinine/kappa, 1)\^-1.209 \* 0.993\^age \* 1.1018(if female) \* 1.159(if black or African American), where kappa is 0.7 for females and 0.9 for males, alpha is -0.329 for females and -0.411 for males, min is minimum of serum creatinine/kappa or 1, and max is the maximum of serum creatinine/kappa or 1. The number of participants with at least a Baseline and a post-Baseline value are presented.

    Time frame: Baseline, Every 6 m until the End of Study (42 m)

07

Results

Posted Oct 2, 2018
Limitations and caveats
The study was discontinued for logistical reasons and not due to either safety concerns or lack of efficacy. The investigators were offered participation in a similar long-term migalastat study for participants ongoing at discontinuation.

Participant flow

Eighty-five eligible participants with Fabry disease who completed treatment with migalastat in one of three previous studies (AT1001-011 \[NCT00925301\], AT1001-012 \[NCT01218659\], or FAB-CL-205 \[NCT00526071\]) were enrolled in this open-label extension study to enable the collection of long-term safety and efficacy data.

Participant flow — Overall Study
MilestoneMigalastat
Started85
Received at least 1 dose of study drug85
Safety population85
Intent to treat (itt) population85
Itt-amenable population68
Completed65
Not completed20
Withdrew: Physician decision4
Withdrew: Withdrawal due to nonamenable mutation1
Withdrew: Pregnancy1
Withdrew: Death2
Withdrew: Adverse event1
Withdrew: Consent withdrawn by participant8
Withdrew: Non-compliance with study drug3

Outcome measures

PrimaryNumber Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered migalastat that did not necessarily have a causal relationship with the treatment. Each AE was recorded at the time of reporting; visits typically occurred every 6 months. A TEAE was defined as an AE starting on or after the first study drug administration date. Serious AEs were life-threatening or resulted in death, persistent or significant incapacitation, inpatient or prolonged hospitalization, or a congenital anomaly. The criteria for AE severity were: Mild: minimal discomfort, does not interfere with normal everyday activities; Moderate: sufficiently discomforting, interferes with normal everyday activities; Severe: prevents normal everyday activities. The number of participants experiencing TEAEs is presented for those who received migalastat treatment. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline to End of Follow-up (30 days after the end of this 42-month study), with AE reporting occurring at each study visit, which occurred once every 6 months.
Reported as:
Number · participants
Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
participantsMigalastat
Participants with at least 1 TEAE74
Participants with at least 1 serious TEAE22
Participants discontinued due to TEAEs1
Participants with adverse events leading to death2
Participants with TEAEs related to study drug14
Participants with TEAEs unrelated to study drug60
Participants with at least 1 mild TEAE22
Participants with at least 1 moderate TEAE40
Participants with at least 1 severe TEAE12
SecondaryAnnualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)

The annualized rate of change of the eGFR was assessed per participant by the slope of the simple linear regression between the observed values and the assessment times. It was calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (eGFR \[CKD-EPI\]) and the Modification of Diet in Renal Disease (MDRD) equation (eGFR \[MDRD\]). The equations are as follows: eGFR \[MDRD\] = 175 \* (Serum Creatinine)\^-1.154 \* (Age)\^-0.203 \* 1.212 (if black or African American) \* 0.742 (if female); eGFR \[CKD-EPI\] = 141 \* min(serum creatinine/kappa,1)\^alpha \* max(serum creatinine/kappa, 1)\^-1.209 \* 0.993\^age \* 1.1018(if female) \* 1.159(if black or African American), where kappa is 0.7 for females and 0.9 for males, alpha is -0.329 for females and -0.411 for males, min is minimum of serum creatinine/kappa or 1, and max is the maximum of serum creatinine/kappa or 1. The number of participants with at least a Baseline and a post-Baseline value are presented.

Time frame:
Baseline, Every 6 m until the End of Study (42 m)
Reported as:
Mean · milliliters/minute/1.73 meters^2
Annualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)
milliliters/minute/1.73 meters^2Migalastat ITT-Amenable Population
EGFR [CKD-EPI]1.54 (-1.63 to 4.71)
eGFR [MDRD]1.40 (-3.14 to 5.94)

Adverse events

Collected over Baseline to End of Follow-up (30 days after the end of this 42-month study), with AE reporting occurring at each study visit, which occurred once every 6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Migalastat—22/85 (25.9%)57/85 (67.1%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventMigalastat
PriapismReproductive system and breast disorders1/33
Implantable defibrillator insertionSurgical and medical procedures2/85
Atrial fibrillationCardiac disorders2/85
PneumoniaInfections and infestations2/85
Uterine polypReproductive system and breast disorders1/52
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/85
Metastatic squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/85
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/85
DeathGeneral disorders1/85
Device malfunctionGeneral disorders1/85
Most frequent other events
Showing 10 of 26
Most frequent other events
EventMigalastat
DiarrhoeaGastrointestinal disorders13/85
HeadacheNervous system disorders11/85
ArthralgiaMusculoskeletal and connective tissue disorders11/85
Pain in extremityMusculoskeletal and connective tissue disorders11/85
NauseaGastrointestinal disorders10/85
DizzinessNervous system disorders9/85
FatigueGeneral disorders9/85
InfluenzaInfections and infestations9/85
NasopharyngitisInfections and infestations9/85
Urinary Tract InfectionInfections and infestations8/85

Baseline characteristics

ITT Population: All participants who received at least 1 dose of study drug after they enrolled into this open-label extension study.

Age, Continuous
Age, Continuous(years)Migalastat
Mean48.8 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)Migalastat
Female52
Male33
08

Study locations

25 sites
  • Atlanta, Georgia 30322, United States
  • Chicago, Illinois 60611, United States
  • Kansas City, Kansas 66160, United States
  • Boston, Massachusetts 02114, United States
  • Grand Rapids, Michigan 49525, United States
  • New York, New York 10016, United States
  • Portland, Oregon 97239, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Dallas, Texas 75246, United States
  • Fairfax, Virginia 22030, United States
  • Seattle, Washington 98195, United States
  • Pilar, B1629ODT, Argentina
  • Adelaide, 5000, Australia
  • Parkville, 3050, Australia
  • Edegem, 2650, Belgium
  • Porto Alegre, 90035-903, Brazil
  • Montreal, H4J 1C5, Canada
  • Copenhagen, 2100, Denmark
  • Cairo, 11451, Egypt
  • Garches, 92380, France
  • Roma, 00168, Italy
  • Barcelona, 08025, Spain
  • Ankara, 06500, Turkey
  • London, NW3 2QG, United Kingdom
  • Salford, M6 8HD, United Kingdom
09

References and documents

Publications

  • Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198. PubMed 27509102 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2011 to primary completion in Feb 2016, 52 months.

Results were first posted in Oct 2018, 2 years 7 months after primary completion. A results delay was requested in May 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2011
First posted
Oct 24, 2011
StartActual
Oct 14, 2011
Primary completionActual
Feb 17, 2016
CompletionActual
Feb 17, 2016
Results delay requested
May 23, 2017
Results first posted
Oct 2, 2018
Last update
Oct 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01458119
Responsible party
Sponsor
First posted
Oct 24, 2011
Start date
Oct 14, 2011
Primary completion
Feb 17, 2016
Completion
Feb 17, 2016
Results posted
Oct 2, 2018
Last update
Oct 2, 2018

Study contacts

Medical Monitor, Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion